SSAT058: A phase IV, open-label, multi centre pilot study to assess changes in cerebral function parameters in patients without perceived Central Nervous System (CNS) symptoms when switched from tenofovir/emtricitabine/efavirenz (Atripla®) to a fixed dose combination of tenofovir/emtricitabine/rilpivirine (Eviplera®). - SSAT058:Atripla to Eviplera switch in patients without CNS symptoms
An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppression - CV risk in HIV patients switching from a boosted PI to DTG
A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal tubular function and renal transporters in HIV-1 antiretroviral naïve patients - SSAT066 Renal Integrase Study
100 项与 St Stephen's Aids Trust 相关的临床结果
0 项与 St Stephen's Aids Trust 相关的专利（医药）
100 项与 St Stephen's Aids Trust 相关的药物交易
100 项与 St Stephen's Aids Trust 相关的转化医学
